54 results about "Cell adhesion molecule" patented technology

Provided are compositions and methods to treat cancers that express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

Provided is a novel anti-CADM1 antibody or an antigen-binding fragment thereof. An anti-CADM1 antibody or antigen-binding fragment thereof according to the present disclosure binds to an epitope comprising amino acid residues at positions 311, 325 and 326 in cell adhesion molecule 1 (CADM1).

The invention provides an application of a carcino-embryonic antigen related cell adhesion molecule 5 (CEACAM5) in treatment of pancreatic cancer. Research finds that a novel stem cell-like cluster cell subtype (hereinafter referred to as' stem cell-like TCs') is found, and the subtype is significantly related to poor prognosis of pancreatic ductal adenocarcinoma patients. Therefore, the invention provides a novel pancreatic ductal adenocarcinoma treatment medicine, namely the carcino-embryonic antigen related cell adhesion molecule 5, which has very positive significance on the treatment of the pancreatic ductal adenocarcinoma.

Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and / or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK / PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.

The present disclosure provides antibodies specifically binding N-terminal or C -terminal regions of Cell Adhesion Molecule-Related / Down-Regulated By Oncogenes (CDON) polypeptide, methods of making the same, and methods of treating humans having tumors by administering the antibody.

The invention belongs to the field of biology, and particularly relates to a chemiluminescence kit for detecting CEACAM1, a use method and application, the chemiluminescence kit comprises a streptavidin magnetic particle working solution, a biotinylated carcino-embryonic antigen related cell adhesion molecule 1 capture antibody solution and an acridinium ester labeled carcino-embryonic antigen related cell adhesion molecule 1 detection antibody solution. Coupling of acridinium ester and the antibody is efficient and simple, repeatability is good, large-scale production and application are easy, a biotin-avidin amplification system (BAS system) is used in a reaction system, quantitative detection of ultramicro markers is more sensitive and more efficient, and compared with a traditional enzyme-linked immunosorbent assay method, the method has the advantages that the detection sensitivity is high, and the sensitivity is high. The magnetic particle chemiluminescence reagent disclosed by the invention has the advantages of low cost, stable and reliable result, high test flux, convenience in production, small batch difference, easiness in large-scale application and the like.

The application relates to the technical field of medicines, and discloses application of gymnemon and a medicine thereof.According to the application, the gymnemon can be used for preparing medicines related to cardiovascular diseases, including medicines for improving heart failure, inhibiting myocardial hypertrophy, improving vascular endothelial function and reducing blood pressure, and further used for preparing medicines for reducing expressions of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 and / or increasing serum NO level; the gymnemon can also be used for preparing medicines for regulating abnormal lipid metabolism, including medicines for reducing triglyceride and total cholesterol level; the gymnemon can also be used for preparing medicines for relieving liver injury, including medicines for reducing glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase level; and the gymnemon can also be used for preparing medicines for improving systemic inflammation and / or platelet and thrombin dysfunction.

The integrin family of cell adhesion molecules has emerged as key mediators of tissue fibrosis. A pharmacological inhibitor of multiple integrin subtypes is required to produce meaningful effects on delaying or inhibiting the progression of fibrosis. Monoclonal antibodies recognizing multiple integrins with potent neutralizing activity and having human and mouse cross-reactivity are described. In particular, monoclonal antibodies that bind human αvβ1, αvβ3, αvβ5, αvβ36, αvβ38, and α5β1 integrins and mouse αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8 integrins are described.

Pharmaceutical compositions comprising anti-CEACAM1mAb and their use in the inhibition of NET-mediated activity and in the prevention and treatment of pathologies associated with these activities are provided, and are exemplified by mAb CM24 that also exhibit effective inhibition of cancer cell migration and NET-induced platelet aggregation. Prognostic methods based on NET-biomarkers for use in patient selection and monitoring of therapeutic efficacy are also presented.

A modified cell is provided that expresses (a) a chimeric antigen receptor targeting GPC3 and / or CD19, and (b) a multispecific antigen binding protein, variant or binding fragment thereof that binds to one or more targets, comprising a first antigen binding protein, variant or binding fragment thereof that binds to EpCAM (epithelial cell adhesion molecule), and a second antigen binding protein, variant or binding fragment thereof, which binds to an immune cell marker, wherein the first antigen binding protein, variant or binding fragment thereof, which binds to EpCAM comprises a heavy chain variable region and / or a light chain variable region comprising a sequence as disclosed herein. Also disclosed are methods of generating / generating cells as disclosed herein and methods of treating with cells as disclosed herein.

Peptides, proteins, antibodies, antibody fragments, or antigen-binding fragments thereof, against cell adhesion molecules for use as immunotherapeutics.

Disclosed are compositions including a population of human enteric neural stem cells (ENSCs), wherein the population comprises at least one of a cell expressing nerve growth factor receptor (NGFR), a cell expressing integrin alpha 6 (ITGA6), a cell expressing L1 cell adhesion molecule (L1CAM), a cell that expresses proteolipid protein 1 (PLP1), and / or a cell that expresses paired-like homeobox 2B (PHOX2B), methods of producing the compositions, and their uses.

Disclosed herein are immune cell engagers. The immune cell engager may include a cell binding domain, an immune cell adhesion molecule, an immune cell costimulatory molecule, or a combination thereof. Methods of use and production are further provided.

The present invention relates to a humanized and affinity matured antibody against CEACAM1. Provided herein are recombinant antibodies, and antigen-binding fragments thereof, useful for binding and inhibiting carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1). Also provided are methods of reducing T cell tolerance and treating cancer using the disclosed CEACAM1 antibodies and antigen binding fragments thereof.

Pharmaceutical compositions containing anti-CEACAM 1 mAbs and their use in inhibiting NET-mediated activities and in the prevention and treatment of conditions associated with these activities are provided, exemplified by mAb CM24, which has also been shown to effectively inhibit cancer cell migration and NET-induced platelet aggregation. Additionally, prognostic methods based on NET biomarkers for use in patient selection and monitoring treatment efficacy are presented.

It is provided a method for analyzing an isolated airway secretion sample of an equine patient in vitro, the method comprising the following steps: a) providing an isolated airway secretion sample originating from an equine patient, b) determining the concentration of at least one protein chosen from the group consisting of mucin-4, polymeric immunoglobulin receptor, carcinoembryonic antigen-related cell adhesion molecule 1, CD177, and vanin 1 in the isolated airway secretion sample, c) determining that the equine patent suffers from equine asthma if the concentration of the at least one protein exceeds a predeterminable threshold.

Methods of using pulsed focused ultrasound (pFUS) therapy to treat pancreatic disorders such as type 1 diabetes, pancreatitis, and pancreatic cancer are provided. The methods utilize pulsed focused ultrasound (pFUS) therapy either by itself or in combination with islet transplantation and / or stem cell therapy to promote regeneration of damaged pancreatic tissue, increase insulin secretion in response to glucose, or improve engraftment and revascularization of transplanted islets or beta cells. Additionally, methods of using pFUS are provided for modulating paracrine secretion in the pancreas, islets, beta cells, or stem cells, or at a transplantation site to therapeutically alter levels of various factors including, without limitation, cytokines, growth factors, angiogenic factors, and cell adhesion molecules.

The present invention relates to a self-assembling selenopeptide targeting vascular cell adhesion molecule-1 (VCAM-1), a selenopeptide nanomedicine, and a preparation method and application thereof. The self-assembling selenopeptide targeting vascular cell adhesion molecule-1 includes an oxidation response unit and a vascular cell adhesion molecule-1 targeting unit sequentially connected from the N-terminus to the C-terminus; the oxidation response unit contains a selenocysteine substituted with a fatty chain. The self-assembling selenopeptide has the ability to sensitively respond and eliminate reactive oxygen species, and can target vascular cell adhesion factor-1 overexpressed in plaque tissue, with excellent active targeting. It can be used alone as a drug for treating atherosclerosis or as a carrier to effectively deliver drugs such as statins to plaque tissue, thereby jointly improving the inflammatory microenvironment of plaque tissue. In addition, the self-assembling selenopeptide as a nanocarrier also significantly improves the enrichment of statins in the liver and increases the bioavailability of statins.

The application belongs to the technical field of micro-robot preparation, and provides a magnetic micro-robot with ROS response and shape self-adaptability, a preparation method and application thereof. The preparation method comprises the following steps: mixing eight-arm polyethylene diamine, eight-arm succinimidyl carboxylate, iron oxide nanoparticles, antioxidant material, cell adhesion molecule and PBS buffer to obtain a mixture; mixing the mixture with n-hexane, liquid paraffin and span 80, and performing magnetic stirring, and then standing to obtain a magnetic micro-robot mixture; and separating the magnetic micro-robot mixture by using a permanent magnet to obtain magnetic gel microspheres, i.e. the magnetic micro-robot. The magnetic micro-robot prepared by the application has ROS response and good shape self-adaptability, and can be widely applied to the medical field.

The invention belongs to the technical field of medicines, and discloses application of berberine serving as an active ingredient of rhizoma coptidis to preparation of a medicine for preventing and / or treating vascular injury. According to the application disclosed by the invention, an action target of berberine serving as a core component of coptis chinensis is predicted through network pharmacology, and then a tumor necrosis factor-alpha stimulated human umbilical vein endothelial cell (HUVEC) model is used for verification; it is proved that berberine down-regulates the expression of downstream key inflammatory factors (IL-6 and IL-8), monocyte chemotactic protein-1 (MCP-1), cell adhesion molecule vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1). Based on this, the invention provides a candidate drug with novel mechanism and multi-target effect for prevention and treatment of atherosclerosis, and has important development value and application prospect.

The invention discloses a culture method for inducing human cerebral cortex organoid differentiation through cell adhesion molecules, and belongs to the technical field of organoid culture. The culture method comprises the following steps: culturing stem cells by using an mTeSR culture solution, screening, decomposing into single cells, centrifugally precipitating, re-suspending in an organoid differentiation culture solution I, inoculating, culturing to the 18th day, transferring an organoid into a low-adhesion culture dish, replacing the culture solution with an organoid differentiation culture solution II, and culturing from the 18th day to the 35th day; replacing the culture solution with an organoid differentiation culture solution III, and culturing from the 35th day to the 70th day; and finally, replacing the culture solution with an organoid differentiation culture solution IV, and culturing after 70th day. The culture method provided by the invention optimizes the culture of cerebral cortex organs, has repeatability, does not interfere with a key signal channel and does not deviate from a physiological development mechanism, and can be widely and accurately used for disease modeling.

The application discloses application of ferritin-carrying neuron-derived extracellular vesicles in auxiliary diagnosis of Parkinson's disease and belongs to the field of biomedical technology. The application realizes effective identification of specific ferritin-carrying neuron-derived extracellular vesicles in a flow cytometer by fluorescence labeling of L1 cell adhesion molecule antibodies and ferritin heavy chain antibodies, and can accurately distinguish PD patients, MSA patients and healthy people by analyzing the concentration of the ferritin-carrying neuron-derived extracellular vesicles in blood plasma, thereby providing an efficient PD diagnosis biomarker and greatly improving the ability of early diagnosis of PD and identification of MSA and PD, and effectively solving the problems of complexity and low sensitivity faced by traditional diagnosis methods.

The present disclosure relates to methods for generating progenitors functionally totipotent blastomere-like stem cells via P ARP -regulated proteomic reprogramming of a PARP- DUX4-NAN0G regulatory axis of conventional human induced pluripotent stem cells (hiPSC) by chemically reverting them to tankyrase / PARP1 inhibitor-regulated naive (TIRN) human stem cells and methods and compositions useful for generating chimeras using such human induced totipotent TIRN stem cells. In certain embodiments, the TIRN stem cells are engineered to express a cell adhesion molecule (e.g., E-Cadherin) or DUX4.

The invention belongs to the technical field of biomedical engineering and cell therapy, and particularly relates to a preparation method of a mesenchymal stem cell exosome capable of improving an anti-inflammatory function. The core is a collaborative design of composite biochemical pre-stimulation and inflammatory microenvironment response type three-function targeting anchoring. A tumor necrosis factor-alpha with a concentration of 5-8 ng / mL, a resveratrol derivative with a concentration of 2-5 [mu] mol / L and glutathione with a concentration of 10-20 [mu] mol / L are adopted for reverse synergistic pre-stimulation, such that an anti-inflammatory pathway is activated; a vascular cell adhesion molecule-1 targeting domain-matrix metalloproteinase-9 sensitive connecting arm-LL-37 anti-inflammatory domain fusion polypeptide is anchored, so that precise targeting and response release are realized. According to the method, the problems of insufficient anti-inflammatory activity, poor targeting and off-target of the exosome are solved, the enrichment amount of an inflammatory site is increased by 2.5-4 times, the TNF-alpha inhibition rate reaches 90%-95%, and the exosome is suitable for treating inflammatory diseases.

The invention discloses a thalassemia treatment method based on a stem cell technology and application. The thalassemia treatment method comprises the following steps: collecting a peripheral blood sample of a patient, and carrying out stem cell isolated culture; constructing a nucleic acid aptamer by combining a vascular cell adhesion molecule-1 and a stromal cell-derived factor-1 in a bone marrow microenvironment; connecting a nucleic acid aptamer, a cell adhesion promoting peptide and a stem cell growth factor, and constructing a homing guiding reagent; preparing nano liposome and nano polymer particles; the nucleic acid aptamer is connected to the surfaces of the nano-liposome and the nano-polymer particles, and is grafted with a temperature-responsive material to obtain the nano-carrier with a responsive release function; stem cell growth factors and platelet-derived growth factors are mixed with gelatin microspheres to form a slow release system; the cultured stem cells are mixed with a homing guide reagent, a nano-carrier and a slow release system, and are transplanted into the body of a patient through intramedullary injection. The stem cell homing efficiency can be improved, and the treatment effect on thalassemia is improved.

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.

Provided are stabilized formulations of the human carcinoembryonic antigen-related cell adhesion molecule 5 (hCEACAM5)-targeted antibody-drug conjugate huMAb2-3-SPDB-DM4, as well as methods for making and using same.30

Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer and infection.

The invention discloses application of neuron-derived extracellular vesicles carrying ferritin in auxiliary diagnosis of Parkinson's disease, and belongs to the technical field of biomedicine. According to the present invention, the L1 cell adhesion molecule antibody and the ferritin heavy chain antibody are subjected to fluorescence labeling, such that the specific ferritin-carrying neuron-derived extracellular vesicle can be effectively identified in the flow cytometry, and the concentration of the ferritin-carrying neuron-derived extracellular vesicle in the plasma is analyzed so as to determine the concentration of the ferritin-carrying neuron-derived extracellular vesicle, compared with the prior art, the kit provided by the invention has the advantages that PD patients, MSA patients and healthy people can be accurately distinguished, an efficient PD diagnosis biomarker is provided, the capabilities of early PD diagnosis and MSA and PD identification are greatly improved, and the problems of complexity and low sensitivity faced by a traditional diagnosis method can be effectively solved.

The present invention relates to a pharmaceutical composition including an IL-32θ mutant for the prevention or treatment of inflammatory diseases and / or cancer and a use thereof. The interleukin-32θ mutant (IL-32θ mutant) of the present invention can inhibit inflammatory cytokines and chemokines, inflammatory mediators and the metastasis and proliferation of cancer through intracellular pathways, and can suppress the expression of Intracellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) in Human Umbilical Vein Endothelial Cells (HUVECs), and thus can be used for preventing and treating inflammatory diseases such as atherosclerosis through the inhibition of monocyte-endothelial cell adhesion. The mutant can also be utilized as a research material for various cancers and / or inflammatory diseases.